sequenti
enzymat
process
coval
attach
ubiquitin
polypeptid
target
protein
process
known
ubiquityl
well
fig
case
singl
ubiquitin
attach
target
protein
wherea
other
multipl
monoubiquitin
adduct
conjug
differ
residu
target
mani
instanc
variou
type
ubiquitin
chain
produc
wherein
one
ubiquitin
moieti
attach
free
amino
group
anoth
lead
linear
ubiquitin
chain
chain
involv
intern
ubiquitin
lysin
residu
well
mix
ubiquitin
chain
contain
differ
linkag
linkag
ubiquitin
ubiquitinlik
protein
ubl
includ
small
ubiquitinlik
modifi
sumo
neuron
precursor
cellexpress
development
downregul
protein
differ
type
ubiquitin
ubl
modif
sometim
refer
ubiquitin
code
specif
divers
effect
protein
cell
physiolog
exampl
modif
target
protein
damag
improperli
fold
intrins
short
halfliv
degrad
via
system
up
appropri
polyubiquityl
protein
recogn
degrad
macromolecular
proteasom
via
mechan
extens
review
instanc
ubiquityl
regul
protein
interact
local
enzymat
activ
therebi
affect
cellular
process
includ
transcript
dna
damag
signal
dna
repair
cell
cycl
progress
endocytosi
apoptosi
variou
control
mechan
often
involv
ubiquitinbind
protein
mani
exist
eukaryot
recent
demonstr
posttransl
modif
ubiquitin
provid
addit
layer
regul
affect
variou
cellular
like
posttransl
modif
ubiquityl
revers
peptidas
term
deubiquityl
enzym
dub
cleav
ubiquitin
substrat
protein
edit
ubiquitin
chain
process
ubiquitin
dub
relat
enzym
involv
edit
process
ubl
prime
exampl
senp
sentrinsumo
specif
proteas
protein
process
sumo
precursor
sumo
dub
classifi
six
famili
base
sequenc
domain
conserv
fig
usp
ubiquitinspecif
proteas
uch
ubiquitin
carboxytermin
hydrolas
mjd
domaincontain
proteas
otu
ovarian
tumour
proteas
mindi
motifinteract
ubiquitincontain
novel
dub
famili
jamm
mpn
famili
senp
first
five
dub
famili
cystein
peptidas
wherea
jamm
zinc
metallopeptidas
ubiquityl
relat
process
control
myriad
aspect
human
cell
biolog
physiolog
defect
process
contribut
mani
diseas
accordingli
dub
deregul
contribut
variou
sporad
genet
disord
notabl
exampl
includ
uch
famili
member
protein
mutat
melanoma
mesothelioma
renal
cell
transloc
aneurysm
bone
mutat
neurolog
whose
mutat
caus
cush
whose
mutat
caus
development
whose
express
dysregul
amplifi
certain
glioblastoma
breast
ovarian
cyld
commonli
mutat
deregul
mjdfamili
dub
also
link
diseas
associ
polyglutamin
amplif
exampl
expans
dna
cag
trinucleotid
repeat
ataxin
caus
diseas
also
known
spinocerebellar
ataxia
furthermor
mutat
jamm
famili
member
associ
molecul
domain
stam
amsh
also
known
stambp
caus
malform
grow
interest
exploit
compon
ubiquityl
machineri
therapeut
although
strong
progress
develop
smallmolecul
inhibitor
ubiquitin
ubl
highli
pleiotrop
natur
mean
drug
like
confin
acut
set
treatment
aggress
cancer
given
greater
number
divers
dub
offer
potenti
develop
drug
specif
effect
particular
group
divers
enzym
welldefin
catalyt
cleft
dub
intrins
attract
potenti
drug
howev
discuss
recent
develop
select
dub
inhibitor
limit
insuffici
understand
dub
biolog
difficulti
establish
robust
biochem
assay
suitabl
compound
screen
limit
cellular
vivo
model
assess
dub
activ
inhibit
pleiotrop
natur
variou
smallmolecul
dub
inhibitor
mani
issu
larg
overcom
rate
progress
dub
drug
discoveri
acceler
past
year
variou
select
compound
describ
character
academ
group
compani
review
discuss
dub
deregul
affect
human
diseas
particularli
cancer
neurodegener
inflamm
tabl
highlight
therapeut
potenti
pharmacolog
modul
dub
activ
recent
advanc
assay
develop
screen
technolog
enabl
research
drug
develop
overcom
recurr
challeng
clinic
translat
dub
inhibitor
also
discuss
success
target
proteasom
cancer
therapi
underlin
clinic
success
bortezomib
broadli
act
proteasom
inhibitor
refractori
multipl
mantl
cell
howev
three
dub
associ
proteasom
function
also
known
may
repres
specif
anticanc
target
facilit
degrad
proteasometarget
substrat
special
dub
remov
ubiquitin
moieti
would
otherwis
imped
entri
proteasom
catalyt
jamm
metalloproteas
highlight
potenti
therapeut
target
studi
show
level
invers
correl
surviv
patient
multipl
myeloma
deplet
impair
prolifer
multipl
myeloma
addit
nuclear
elev
hepatocellular
carcinoma
correl
overexpress
tumour
also
report
regul
ubiquityl
stabil
oncogen
receptor
tyrosin
kinas
ref
furthermor
connect
promot
cellular
respons
dna
doublestrand
break
particularli
process
homolog
recombin
inhibit
could
potenti
sensit
cancer
cell
dnadamag
agent
andor
preferenti
kill
cancer
cell
reli
strongli
homolog
anoth
potenti
anticanc
therapeut
target
primarili
associ
proteasom
regulatori
subunit
potenti
ubiquitin
constitut
activ
revers
associ
subunit
also
known
enhanc
inhibit
proteasom
degrad
conjug
trim
ubiquitin
chain
protein
substrat
express
upregul
nonsmallcel
lung
cancer
especi
level
reportedli
elev
ovarian
cancer
line
connect
sever
import
signal
pathway
exampl
substrat
akt
mediat
intracellular
signal
growth
modul
dishevel
protein
key
posit
regul
wnt
like
dub
revers
interact
bind
receptor
also
known
manner
enhanc
isopeptidas
key
function
remov
distal
ubiquitin
moieti
polyubiquityl
protein
therebi
liber
protein
facilit
destruct
certain
substrat
describ
induc
nitric
oxid
synthas
nuclear
therefor
seem
like
suppress
destruct
certain
protein
promot
degrad
other
notabl
rna
interfer
studi
show
deplet
either
alon
detect
effect
cell
growth
proteasom
structur
proteolyt
capac
acceler
cellular
protein
contrast
deplet
dub
decreas
protein
degrad
suggest
overlap
function
overexpress
epitheli
ovarian
cancer
associ
advanc
tumour
progress
poor
clinic
also
overexpress
hepatocellular
carcinoma
shown
promot
cell
migrat
proteasomeassoci
dub
repres
attract
drug
target
inhibit
might
substanti
effect
cancer
cell
physiolog
fewer
toxic
seen
drug
target
core
proteasom
catalyt
inde
tabl
advanc
report
dub
inhibitor
recent
phase
trial
suspend
treatment
multipl
myeloma
solid
describ
target
ref
ringexpand
version
compound
also
known
identifi
cellbas
screen
look
compound
induc
apoptosi
cell
treat
accumul
polyubiquitin
claim
target
possibl
also
ref
compound
report
revers
reason
select
cellbas
activ
probe
assay
median
inhibitori
concentr
purifi
proteasom
dub
activ
display
strong
activ
test
variou
vivo
solid
tumour
includ
multipl
remain
seen
whether
select
suffici
deliv
promis
nextgener
proteasom
inhibitor
cleav
bioscienc
also
publish
seri
patent
applic
describ
compound
inhibit
jamm
proteas
provid
potenti
angl
develop
select
tabl
one
hallmark
cancer
downregul
loss
deregul
certain
dna
repair
ddr
pathway
andor
strong
relianc
dna
repair
ddr
mechan
regul
posttransl
modif
ubiquityl
mani
dub
strongli
link
one
exampl
dub
identifi
regul
fanconi
anaemia
group
protein
ubiquityl
key
protein
involv
fanconi
anaemia
pathway
dna
crosslink
influenc
accumul
fanconi
anaemia
core
complex
dna
damag
site
deubiquityl
cell
cycledepend
also
remov
monoubiquitin
prolifer
cell
nuclear
antigen
pcna
dna
replic
compon
also
function
dna
repair
translat
activ
includ
involv
feedback
loop
limit
ddr
protein
kinas
regul
cellular
differenti
osteosarcoma
cell
deubiquityl
henc
affect
stabil
inhibitor
dnabind
vitro
activ
greatli
stimul
factor
also
known
enhanc
catalyt
turnov
kcat
affin
km
monoubiquityl
select
inhibitor
submicromolar
potenc
one
pimozid
shown
resensit
platinumresist
nonsmallcel
lung
cancer
cell
promot
pcna
howev
although
studi
indic
ontarget
effect
dub
select
profil
suggest
pimozid
might
less
select
initi
optim
certain
screen
hit
gener
addit
notabl
select
pyrimidin
core
compound
tabl
molecul
alloster
block
complex
format
ref
potenti
cisplatin
cytotox
increas
pcna
monoubiquityl
far
howev
littl
progress
made
advanc
select
inhibitor
clinic
develop
anoth
dub
link
dna
repair
initi
describ
form
complex
ddr
tumour
suppressor
breast
cancer
type
suscept
protein
promot
dna
doublestrand
break
repair
pathway
homolog
deplet
shown
sensit
cell
olaparib
also
known
inhibit
ddr
enzym
poli
adpribos
polymeras
recent
interact
partner
local
function
cooper
dna
repair
shown
ubiquitin
control
ubiquityl
suppress
interact
manner
counteract
ref
current
report
inhibitor
topoisomeras
inhibitor
tabl
although
author
report
low
nanomolar
potenc
pancreat
ductal
adenocarcinoma
cell
surviv
model
develop
compound
report
given
appar
amen
smallmolecul
inhibit
notabl
dub
close
relat
recent
shown
involv
ddr
promot
earli
stage
homolog
maintain
dna
replic
fork
stabil
dna
damag
checkpoint
respons
regul
protein
claspin
may
repres
anoth
potenti
therapeut
target
shown
affect
radiosensit
glioblastoma
cell
myeloid
cell
leukaemia
depend
independ
bestdescrib
inhibitor
tabl
identifi
screen
janu
kinas
inhibitor
shown
inhibit
well
dub
shown
mass
spectrometri
coval
mechan
action
compound
variou
dub
report
connect
tumoursuppress
oncogen
function
may
therefor
repres
potenti
therapeut
regul
sever
dub
link
regul
tumour
suppressor
protein
pivot
role
cellular
stress
respons
lost
mutat
mani
human
doubl
minut
also
known
ringtyp
ubiquitin
ligas
key
neg
regul
abil
ubiquityl
target
cleav
ubiquitin
chain
counteract
proteasom
degrad
lead
suppress
increas
ubiquityl
theori
inhibit
therefor
trigger
degrad
stabil
ultim
activ
apoptot
pathway
tumour
addit
target
also
describ
phosphatas
tensin
homologu
pten
forkhead
box
protein
ref
suggest
altern
therapeut
mechan
inhibitor
also
recent
shown
promot
dna
replic
via
act
dub
ubl
first
publish
submicromolar
inhibitor
ref
shown
rather
nonspecif
inhibitor
recent
moreselect
amidotetrahydroacridin
deriv
identifi
although
exhibit
fairli
low
despit
shown
coval
bind
catalyt
cy
residu
prefer
cysteinyl
group
stabil
promot
arrest
apoptosi
progenra
thiophen
chemic
seri
also
provid
rel
nonspecif
inhibitor
includ
compound
ref
multipl
myeloma
cell
stabil
inhibit
tumour
growth
wherea
anim
model
well
toler
inhibit
tumour
growth
prolong
recent
vivo
studi
use
within
orthotop
neuroblastoma
mous
model
show
statist
signific
inhibit
xenograft
find
encourag
littl
known
bind
mode
compound
whether
optim
druglik
entiti
recent
almac
discoveri
genentech
report
fragmentbas
screen
provid
hit
start
point
discoveri
optim
one
hit
assist
xray
crystallographi
produc
noncoval
highli
select
inhibitor
tabl
stabil
also
recent
report
regul
dub
ref
shown
bind
deubiquityl
result
stabil
delet
result
destabil
wherea
ectop
express
induc
express
target
gene
promot
apoptosi
whether
inhibitor
could
exploit
treat
cancer
diseas
remain
establish
anoth
dub
recent
connect
function
togeth
protein
promot
transcript
furthermor
mutat
human
cancer
cell
report
antagon
tumour
suppressor
fbox
domaincontain
protein
highlight
potenti
inhibitor
variou
tumour
especi
colorect
also
report
antagon
ubiquitindepend
degrad
oncogen
product
myc
well
jun
although
inhibitor
yet
report
seem
like
drug
discoveri
activ
underway
anoth
tumour
suppressor
link
dub
activ
von
vhl
protein
ubiquityl
hypoxiainduc
factor
cellular
oxygen
level
normal
lead
degrad
also
known
report
deubiquityl
number
protein
includ
deubiquityl
prevent
proteasom
degrad
allow
transcript
hypox
respons
gene
thu
inhibit
potenti
suppress
prolifer
hypox
tumour
cell
glaxosmithklin
gsk
present
brief
detail
search
inhibitor
confer
ref
tabl
egfr
ubiquityl
serv
signal
deliv
membran
receptor
cell
surfac
lysosom
mammalian
cell
mechan
intens
studi
epiderm
growth
factor
receptor
egfr
upon
egf
bind
activ
egfr
rapidli
intern
transport
via
earli
late
endosom
lysosom
egfr
degrad
also
known
ubpi
deubiquityl
egfr
earli
endosom
rescu
egfr
sever
tumour
includ
glioblastoma
lung
breast
cancer
egfr
amplifi
mutat
tyrosin
kinas
domain
result
deregul
receptor
signal
drive
uncontrol
prolifer
tumour
inhibitor
exampl
similar
structur
class
identifi
ref
report
tabl
moreov
deriv
compound
shown
efficaci
mous
model
lung
regul
transform
growth
pathway
thought
import
prolifer
glioblastoma
bind
ubiquitin
protein
ligas
complex
deubiquityl
stabil
type
receptor
lead
enhanc
signal
gene
amplifi
glioblastoma
breast
ovarian
cancer
high
express
correl
high
deplet
reduc
oncogen
capac
patientderiv
gliomainiti
cell
owe
diminish
signal
suggest
therapeut
potenti
develop
inhibitor
addit
shown
deubiquityl
receptorregul
smad
rsmad
anoth
set
signal
pathway
compon
dub
normal
express
predominantli
neuron
neuroendocrin
highli
express
mani
cancer
express
correl
poor
although
report
tumoursuppress
role
evid
support
role
inde
transgen
mous
model
constitut
activ
sporad
tumour
develop
mani
moreov
vitro
tumorigenesi
studi
show
express
stimul
oncogenesi
invas
wherea
deplet
antitumour
effect
block
cell
migrat
lung
cancer
cell
precis
mechan
contribut
tumorigenesi
remain
unclear
although
report
suggest
contribut
cell
surviv
signal
cell
cycl
regul
dna
repair
regul
pool
free
ubiquitin
way
affect
protein
degrad
inhibitor
describ
potent
isatin
oacyl
oxim
tabl
select
ref
addit
seri
pyridinon
identifi
moder
enzym
kinet
studi
reveal
compound
uncompetit
inhibitor
select
exhibit
inhibit
cystein
hydrolas
test
use
xray
crystallographi
weak
tripeptid
fluoromethyl
keton
inhibitor
subsequ
shown
bind
within
activ
site
irrevers
modifi
activesit
mission
therapeut
also
develop
sever
seri
potent
select
although
inhibitor
demonstr
antitumour
activ
vivo
induc
deplet
shown
caus
diseas
regress
orthotop
multipl
myeloma
mous
anoth
dub
associ
oncogenesi
catalyt
subunit
deubiquitylas
modul
saga
complex
bestcharacter
substrat
saga
complex
includ
sever
acetyl
site
histon
ubiquityl
site
histon
posttransl
modif
regul
gene
strong
link
identifi
microarray
screen
part
deathfromcanc
signatur
highli
aggress
therapyresist
tumour
later
shown
act
oncogen
product
regul
cell
cycl
progress
prolifer
increas
express
connect
poor
prognosi
sever
cancer
includ
breast
well
oesophag
squamou
cell
oral
squamou
cell
dub
activ
link
surviv
progress
cancer
inhibitor
may
provid
attract
prospect
new
therapi
given
role
ubiquitin
modif
dub
mani
inflammatori
process
see
well
renew
interest
target
immun
system
fight
cancer
antineoplast
potenti
therapeut
inhibit
dub
involv
immun
system
investig
among
posit
regul
stabil
crucial
transcript
factor
control
differenti
regulatori
cell
treg
cell
search
dub
contribut
stabil
cell
shown
upregul
activ
use
report
furthermor
deplet
treg
cell
result
downregul
compromis
express
treg
signatur
gene
impair
suppress
treg
cell
restrict
antitumour
immun
respons
promot
tumour
result
suggest
deplet
treg
cell
target
offer
promis
anticanc
immunotherapi
regard
mission
therapeut
investig
immunooncolog
target
develop
inhibitor
see
mission
therapeut
pipelin
inform
mitochondri
dysfunct
up
impair
describ
hallmark
implic
aetiopathogenesi
mani
agerel
diseas
particularli
neurodegen
disord
alzheim
diseas
parkinson
diseas
accord
connect
ubiquityl
close
link
mitochondri
function
up
maintain
mitochondri
homeostasi
regul
organel
dynam
mitochondri
proteom
convers
mitochondri
dysfunct
impair
cellular
protein
homeostasi
gener
oxid
damag
notabl
mutat
ubiquitin
ligas
parkin
causal
associ
certain
case
famili
parkinson
parkin
ubiquityl
mitochondri
compon
thu
promot
turnov
mitochondria
lysosomemedi
mitophagi
defect
mitophagi
accumul
defect
mitochondria
caus
enhanc
oxid
stress
could
underli
caus
parkinson
corollari
parkin
activ
inhibit
factor
counteract
parkin
could
provid
opportun
diseas
allevi
screen
dub
oppos
parkin
function
identifi
mitochondrionassoci
dub
antagonist
parkinmedi
deplet
significantli
decreas
mitochondri
number
cell
phenotyp
rescu
wildtyp
catalyt
inact
furthermor
deplet
vivo
provid
stress
protect
drosophila
melanogast
model
parkinson
diseas
line
find
deplet
human
hela
cell
led
elong
interconnect
suggest
role
regul
mitochondri
fusion
fission
current
model
invok
function
normal
physiolog
condit
prevent
inappropri
mitophagi
howev
respons
stress
membran
depolar
parkin
recruit
mitochondria
promot
accordingli
condit
mitochondri
dysfunct
exampl
caus
defect
parkin
posit
regul
thought
counteract
clearanc
damag
mitochondria
lead
buildup
metabol
energet
defici
thu
hypothes
context
certain
mitochondri
dysfunct
inhibit
would
therapeut
benefit
far
one
chemic
inhibitor
describ
tabl
induc
mitochondri
elong
mous
fibroblast
effect
cell
mission
therapeut
explor
inhibit
treatment
parkinson
diseas
mitochondri
disord
publish
sever
patent
applic
describ
two
dub
connect
mitophagi
notabl
deplet
found
delay
parkin
transloc
onto
depolar
mitochondria
well
mitochondri
clearanc
display
abil
remov
ubiquitin
chain
parkin
addit
shown
remov
ubiquitin
chain
protein
known
aggreg
often
ubiquityl
form
lewi
bodi
associ
neurodegen
diseas
parkinson
diseas
deplet
either
human
cell
melanogast
result
increas
lysosom
degrad
meanwhil
identifi
parkininteract
protein
coloc
hela
cell
overexpress
parkin
overexpress
wildtyp
catalyt
dead
strongli
inhibit
furthermor
deplet
endogen
enhanc
mitophagi
hela
cell
human
dopaminerg
neuron
cell
line
primari
fibroblast
human
deubiquityl
parkin
basal
condit
cell
treat
mitochondri
depolar
agent
deplet
also
seem
affect
parkin
transloc
although
oppos
parkinmedi
mitochondri
ubiquityl
final
loss
melanogast
found
rescu
locomotor
defect
accumul
dysfunct
mitochondria
flight
muscl
parkinknockout
collect
find
highlight
potenti
inhibitor
parkinson
diseas
perhap
diseas
associ
mitochondri
dysfunct
highlight
connect
parkinson
diseas
dub
shown
interact
parkin
manner
counteract
parkin
addit
recent
shown
remov
ubiquitin
chain
protein
aggreg
accumul
lewi
bodi
hallmark
parkinson
diseas
describ
remov
ubiquitin
certain
substrat
target
proteasom
thu
rescu
substrat
degrad
maintain
pool
free
tabl
revers
smallmolecul
inhibitor
shown
target
catalyt
site
promot
degrad
sever
overexpress
protein
tau
tar
dnabind
protein
whose
accumul
link
neurodegen
notabl
promot
degrad
murin
embryon
cell
suggest
compound
function
specif
furthermor
reduc
accumul
menadioneinduc
oxid
protein
amelior
menadion
hydrogen
peroxideinduc
cell
death
human
proteostasi
therapeut
collabor
biogen
develop
inhibitor
clearanc
aggregationpron
protein
includ
parkinson
diseas
tau
alzheim
diseas
see
proteostasi
pipelin
inform
publish
sever
patent
applic
describ
despit
grow
interest
therapeut
target
cancer
neurodegener
fact
loss
caus
sever
morbid
postnat
lethal
requir
investig
especi
regard
role
neuromuscular
junction
neuromuscular
phenotyp
axj
mice
rescu
neuronalspecif
express
ref
furthermor
extent
contribut
clearanc
protein
involv
neurodegener
vivo
remain
develop
use
inhibitor
diseaserelev
model
may
shed
light
issu
hope
defin
potenti
therapeut
window
inhibit
diseas
set
syndrom
congenit
disord
driven
triplic
human
chromosom
gene
resid
report
regul
cell
cycl
progress
gene
express
deubiquityl
histon
defect
haematopoiet
stem
cell
selfrenew
mous
model
syndrom
rescu
reduc
express
level
similar
control
addit
overexpress
normal
human
fibroblast
neural
progenitor
led
reduc
cell
similar
strong
prolifer
defect
observ
fibroblast
individu
thu
key
regul
control
stem
cell
selfrenew
senesc
syndrom
suggest
inhibitor
might
provid
therapeut
benefit
individu
debilit
autoimmun
diseas
rang
genet
compon
crohn
diseas
diabet
mellitu
type
grave
diseas
rheumatoid
sporad
condit
includ
coeliac
diseas
inflammatori
bowel
diseas
multipl
sclerosi
psoriasi
system
lupu
erythematosu
addit
chronic
inflammatori
diseas
character
prolong
persist
proinflammatori
state
includ
autoimmun
diseas
well
metabol
syndrom
neurodegen
diseas
chronic
obstruct
pulmonari
diseas
cardiovascular
diseas
follow
pattern
recognit
receptor
stimul
dendrit
cell
secret
variou
cytokin
regul
differenti
cell
differ
subset
helper
cell
th
cell
includ
induc
treg
cell
follicular
helper
cell
cell
mediat
proinflammatori
function
secret
proinflammatori
cytokin
includ
ref
moreov
cell
implic
develop
autoimmun
diseas
multipl
sclerosi
rheumatoid
arthriti
system
lupu
shown
stabil
nuclear
receptor
retinoidrel
orphan
cell
propos
possibl
therapeut
target
rheumatoid
one
report
show
highli
express
cell
deplet
result
decreas
well
addit
use
report
inhibitor
vialinin
tabl
also
diminish
furthermor
express
mrna
shown
significantli
elev
cell
patient
rheumatoid
arthriti
compar
healthi
provid
evid
role
rheumatoid
arthriti
trabid
also
known
requir
tlrmediat
express
inflammatori
cytokin
dendrit
propos
trabid
deubiquityl
stabil
histon
demethylas
jumonji
domaincontain
protein
also
known
regul
histon
modif
promot
facilit
recruit
famili
member
condit
delet
dendrit
cell
impair
product
gener
subset
inflammatori
cell
render
mice
refractori
induct
experiment
autoimmun
encephalomyel
eae
anoth
dub
associ
activ
cell
although
dub
extens
studi
context
viral
infect
regul
interact
requir
cell
differenti
autoimmun
consist
mice
resist
cell
receptor
signal
shown
facilit
dub
cellular
zinc
finger
protein
cezann
also
known
bind
deubiquityl
protein
thu
prevent
interact
neg
regulatori
cytoplasm
protein
tyrosin
kinas
play
crucial
part
cell
signal
recruit
phosphoryl
site
cell
receptor
subsequ
phosphoryl
src
kinas
lck
phosphoryl
requir
full
activ
downstream
phosphoryl
adaptor
protein
facilit
cell
addit
cezannedefici
mice
exhibit
attenu
cell
respons
bacteri
infect
refractori
young
mice
similar
naiv
memorylik
cell
compar
wildtyp
mice
older
mice
defici
cezann
reduc
cell
similar
cell
cell
capac
caus
inflamm
autoimmun
diseas
develop
differenti
function
cell
driven
tbox
transcript
factor
tbet
also
known
promot
immun
respons
primarili
promot
express
cytokin
dub
shown
deubiquityl
stabil
tbet
result
enhanc
secret
addit
mrna
express
found
elev
peripher
blood
mononuclear
cell
patient
asthma
compar
healthi
although
current
unclear
mani
dub
involv
regul
immun
respons
possibl
differ
dub
function
distinct
cell
type
mani
publish
studi
base
cell
line
overexpress
system
express
endogen
dub
variou
immun
cell
import
area
futur
investig
similarli
gener
genet
model
develop
inhibitor
cezann
trabid
help
determin
therapeut
potenti
ubiquityl
import
modul
interact
includ
activ
innat
immun
signal
pathway
perhap
surpris
variou
virus
gene
dub
use
strategi
inhibit
ubiquitin
antivir
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
two
six
known
human
coronavirus
highli
pathogen
potenti
humantohuman
transmiss
contain
papainlik
cystein
proteas
term
sarscov
plpro
merscov
plpro
respect
addit
process
viral
polyprotein
proteas
remov
ubiquitin
host
cell
factor
result
antagon
host
antivir
immun
henc
sarscov
plpro
merscov
plpro
propos
import
antivir
target
xray
structur
proteas
shown
structur
similar
usp
famili
otu
domaincontain
proteas
divers
rna
virus
includ
nairovirus
crimeancongo
haemorrhag
fever
viru
dugb
viru
papainlik
proteas
domain
arteriviru
equin
arter
viru
proteas
pro
domain
tymoviru
turnip
yellow
mosaic
viru
hydrolys
ubiquitin
cellular
target
mani
positivestrand
rna
virus
includ
arterivirus
tymovirus
encod
polyprotein
posttransl
cleav
intern
proteas
domain
accord
arteriviru
tymoviru
prodomaincontain
proteas
crucial
requir
viral
replic
due
primari
role
polyprotein
thu
viral
otu
domaincontain
proteas
may
repres
promis
therapeut
target
bacteria
use
repertoir
effector
protein
target
eukaryot
ubiquitin
system
promot
bacteri
pathogen
proteas
activ
human
bacteri
pathogen
includ
salmonella
enterica
serovar
typhimurium
ssel
escherichia
coli
elad
shigella
flexneri
shice
chlamydia
trachomati
rickettsia
bellii
rickc
legionella
pneumophila
subsp
pneumophila
legc
recent
legc
show
proteolyt
activ
ssel
elad
shice
demonstr
ubiquitinspecif
proteas
activ
wherea
rickc
cleav
ubiquitin
lesser
extent
peptid
interestingli
dub
encod
human
pathogen
show
strong
prefer
ubiquitin
chain
target
chain
later
time
point
higher
enzym
concentr
therefor
bacteri
dub
potenti
therapeut
target
addit
express
dub
target
host
function
similar
virus
bacteria
eukaryot
parasit
also
possess
ubl
pathway
use
ubiquitinbas
activ
probe
identifi
dub
plasmodium
falciparum
led
identif
shown
deubiquityl
activ
also
abil
remov
adduct
ubl
ref
investig
parasit
toxoplasma
gondii
use
similar
strategi
identifi
four
dub
one
ortholog
mammalian
ref
structur
studi
explain
dual
specif
enzym
found
requir
parasit
distinct
differ
ubiquitinbind
site
human
counterpart
suggest
parasit
dub
select
target
inhibitor
base
find
great
interest
explor
antiinfect
opportun
dub
inhibitor
understand
mechan
action
individu
dub
import
initi
screen
subsequ
drug
discoveri
campaign
dub
gener
isopeptidas
case
catalys
proteolyt
reaction
lysin
chain
carboxyl
group
correspond
ubiquitin
c
last
two
ctermin
amino
acid
residu
glycin
lack
side
chain
result
narrow
linker
either
side
isopeptid
bond
mirror
long
narrow
dub
catalyt
moreov
cysteinyl
proteas
dub
catalyt
activ
tend
reli
two
three
crucial
residu
compris
catalyt
diad
triad
gener
contain
side
chain
lower
pka
catalyt
cy
lead
nucleophil
attack
substrat
isopeptid
collect
properti
bring
complex
identif
select
smallmolecul
inhibitor
target
dub
catalyt
site
like
restrict
breadth
seri
suitabl
develop
potent
select
dub
inhibitor
proteostasi
thiophen
pyrimidin
corederiv
inhibitor
known
bind
ubiquitin
pocket
prevent
ubiquityl
substrat
howev
major
histor
current
dub
drug
discoveri
programm
focus
chemic
seri
includ
provis
activ
warhead
form
revers
irrevers
coval
adduct
dub
catalyt
cystein
high
reactiv
warhead
includ
oxid
alkyl
aryl
like
limit
drug
select
may
hamper
develop
accept
pharmacokinet
pharmacodynam
paramet
may
also
pose
risk
idiosyncrat
toxic
patient
reason
lessreact
warhead
explor
close
relat
warhead
util
nondub
cystein
proteas
inhibitor
clinic
exampl
inhibitor
identifi
librari
amidomethyl
methyl
acryl
compound
contain
michael
acceptor
group
also
found
rupintrivir
inhibitor
rhinoviru
proteas
gsk
cathepsin
c
addit
inhibitor
ref
contain
michael
acceptor
group
similar
found
principia
biopharma
bruton
tyrosin
kinas
btk
howev
exampl
number
compound
weak
dub
inhibitor
mission
therapeut
discov
coval
activesit
seri
druglik
unrel
previous
describ
dub
inhibitor
achiev
submicromolar
cellbas
potenc
exhibit
good
oral
peptidas
includ
mani
cystein
proteas
recogn
small
linearpolypeptid
motif
cleav
either
peptid
dub
howev
complex
dub
cleav
isopeptid
linkag
side
chain
lysin
residu
ctermin
glycin
ubiquitin
isopeptid
linkag
provid
specif
flexibl
mechan
also
dub
need
accommod
substanti
globular
posttransl
modif
ubiquitin
ubl
chain
catalyt
furthermor
unlik
cystein
peptidas
catalyt
triad
cysteinyl
peptidas
dub
usual
function
configur
alloster
regul
requir
render
dub
fulli
function
process
alloster
regul
substratemedi
exampl
otulin
trigger
intramolecular
reorgan
exampl
induc
key
cofactor
addit
sever
dub
associ
multiprotein
complex
valosincontain
protein
vcp
also
known
associ
alloster
regul
affin
dub
instanc
dub
coexist
complex
ubiquityl
issu
must
therefor
care
consid
establish
screen
compound
evalu
assay
dub
dub
inhibitor
suggest
target
alloster
site
inhibitor
ref
approxim
twenti
year
ago
gener
assay
establish
measur
dub
enzymat
activ
base
substrat
ubiquitin
ctermin
methylcoumarin
ubamc
substrat
effici
cleav
hydrolys
variou
dub
releas
highli
fluoresc
amc
moieti
assay
use
variou
dub
inhibitor
screen
exampl
identifi
ref
ref
inhibitor
one
signific
drawback
prone
fluoresc
interfer
exhibit
mani
small
moreov
amc
altern
tag
rhodamin
tetramethylrhodamin
tamra
use
less
prone
fluoresc
artefact
contain
peptid
linkag
thu
differ
quit
substanti
natur
dub
substrat
process
substrat
thu
requir
dub
function
nonphysiolog
manner
therebi
potenti
diminish
prospect
identifi
compound
oper
cellular
therapeut
set
challeng
develop
dub
inhibitor
screen
assay
oxid
hydrolysi
activesit
cysteinyl
residu
purifi
dub
biochem
buffer
sensit
requir
use
protect
reduc
agent
dithiothreitol
dtt
usual
millimolar
concentr
maintain
dub
enzymat
activ
alter
concentr
type
reduc
agent
exampl
cystein
glutathion
tri
phosphin
tcep
consider
affect
inhibit
obtain
hit
follow
highthroughput
screen
identifi
inhibitor
abil
compound
inhibit
presenc
differ
reduct
mani
compound
show
greatest
inhibit
absenc
reduct
less
potent
presenc
cystein
glutathion
least
potent
presenc
dtt
tcep
subset
molecul
show
altern
profil
demonstr
inhibit
presenc
dtt
tcep
final
set
molecul
inhibit
addit
reduct
ad
togeth
data
demonstr
critic
natur
reduc
environ
dub
activ
inhibit
thu
screen
base
high
concentr
reduc
agent
use
firstgener
fluoresc
substrat
gener
high
falseposit
rate
issu
like
signific
challeng
identifi
genuin
select
dub
inhibitor
inde
nonselect
natur
dub
inhibitor
highlight
biochem
selectivityprofil
assay
rel
dub
inhibitor
report
literatur
show
promis
matrixassist
laser
desorptionion
timeofflight
malditof
mass
spectrometri
use
screen
dub
activ
specif
systemat
assess
specif
recombin
human
dub
diubiquitin
isom
possibl
chain
linkag
linear
subsequ
panel
dub
screen
report
dub
inhibitor
find
demonstr
none
compound
display
strong
select
toward
singl
dub
mani
inhibit
dub
panel
novel
technolog
base
chemic
synthes
dub
substrat
contain
isopeptid
linkag
ubiquitin
chain
andor
assay
technolog
less
prone
fals
posit
luminesc
timeresolv
fluoresc
mass
spectrometri
advanc
screen
campaign
therefor
exampl
substrat
use
varieti
dub
demonstr
suitabl
assay
window
highthroughput
subsequ
use
repres
dub
demonstr
statist
robust
reagent
screen
campaign
inhibitor
believ
develop
crucial
optim
prospect
identifi
develop
dub
inhibitor
ultim
clinic
use
key
issu
studi
dub
modul
cell
understand
substrat
specif
dub
prefer
monoubiquityl
substrat
wherea
other
favour
specif
ubiquitin
chain
type
chain
bear
mix
linkag
mix
chain
contain
ubiquitin
furthermor
mani
dub
specif
substrat
protein
mediat
mechan
often
involv
region
dub
distinct
catalyt
site
dub
substrat
determin
biochemistri
yeast
twohybrid
interact
proteom
profil
often
challeng
timeconsum
clearli
abil
directli
monitor
dub
activ
within
nativ
biolog
system
essenti
understand
physiolog
patholog
role
individu
dub
well
effect
dub
dub
activ
cell
monitor
chemic
probe
gener
readili
detect
coval
complex
dub
catalyt
site
recent
review
ref
activ
probe
label
dub
base
catalyticsit
thiol
dub
reactiv
toward
probe
depend
type
electrophil
warhead
fuse
ubiquitin
addit
profil
dub
level
activ
catalyt
inhibit
activ
probe
also
use
identifi
dub
affin
purif
combin
mass
recent
activitybas
probe
abp
bear
fluoresc
report
tag
gener
replac
initi
tag
exampl
haemagglutinin
ha
epitop
allow
fluoresc
imag
instead
detect
although
product
ubiquitin
abp
histor
base
trypsincatalys
transpeptid
modifi
ubiquitin
c
terminu
vinyl
sulfon
group
recent
approach
involv
full
chemic
synthesi
ubiquitin
advanc
allow
incorpor
modifi
amino
acid
residu
posit
abp
whether
natur
mass
spectrometri
becom
import
tool
monitor
ubiquitin
adduct
well
chang
ubiquitin
inde
combin
abp
immunoblot
mass
spectrometri
gener
power
tool
monitor
dub
activ
inhibit
small
well
assess
target
engag
cell
tissu
exampl
one
studi
use
abp
demonstr
select
cell
contrast
inhibit
broad
rang
addit
anoth
studi
demonstr
cellular
select
panel
dub
use
abp
activitybas
proteom
probe
facilit
develop
pharmacolog
activ
enzym
inhibitor
approach
repres
cellbas
assay
treatment
inhibitor
carri
intact
cell
allow
rang
cellular
enzym
assess
competit
assay
inhibitor
abp
lead
reduc
label
profil
abp
loss
signal
abplabel
target
enzym
allow
assess
specif
inhibit
limit
approach
howev
number
enzym
success
label
abp
represent
activ
enzym
cellular
proteom
abp
use
character
dub
inhibitor
immunoprecipit
combin
identif
labelfre
quantif
mass
spectrometrybas
use
approach
quantit
data
cellular
dub
obtain
confirm
broad
dub
inhibitor
wherea
found
select
inhibitor
may
therefor
provid
basi
explor
therapeut
opportun
oncolog
see
preced
section
tabl
past
decad
wit
dramat
advanc
understand
dub
function
mechan
action
regul
diseas
linkag
parallel
major
improv
dub
biochem
assay
screen
technolog
lead
develop
increas
number
smallmolecul
dub
inhibitor
whose
select
explor
possibl
refin
inhibitor
provid
basi
druglik
molecul
suitabl
clinic
evalu
also
provid
versatil
tool
investig
dub
cell
biolog
regul
biochem
mechan
well
test
therapeut
hypothes
diseas
model
although
still
earli
predict
extent
broad
therapeut
potenti
dub
next
year
certainli
seem
set
produc
excit
develop
arena
dub
biolog
drug
discoveri
springer
natur
remain
neutral
regard
jurisdict
claim
publish
map
institut
affili
